First Trust Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $94.5M | Buy |
1,672,491
+505,692
| +43% | +$29.5M | 0.07% | 362 |
|
|
2025
Q4 | $69.3M | Buy |
1,166,799
+271,837
| +30% | +$14.8M | 0.05% | 437 |
|
|
2025
Q3 | $48.5M | Buy |
894,962
+156,480
| +21% | +$8.95M | 0.04% | 575 |
|
|
2025
Q2 | $40.6M | Buy |
738,482
+69,001
| +10% | +$4.06M | 0.03% | 647 |
|
|
2025
Q1 | $47.3M | Buy |
669,481
+39,496
| +6% | +$2.66M | 0.04% | 556 |
|
|
2024
Q4 | $41.4M | Buy |
629,985
+162,687
| +35% | +$10.9M | 0.04% | 609 |
|
|
2024
Q3 | $32.8M | Buy |
467,298
+63,274
| +16% | +$5.29M | 0.03% | 633 |
|
|
2024
Q2 | $33.3M | Sell |
404,024
-72,507
| -15% | -$6.04M | 0.03% | 617 |
|
|
2024
Q1 | $41.6M | Sell |
476,531
-103,400
| -18% | -$9.26M | 0.04% | 536 |
|
|
2023
Q4 | $55.9M | Buy |
579,931
+56,532
| +11% | +$5M | 0.06% | 406 |
|
|
2023
Q3 | $46.3M | Buy |
523,399
+17,438
| +3% | +$1.55M | 0.05% | 439 |
|
|
2023
Q2 | $43.9M | Buy |
505,961
+12,099
| +2% | +$1.14M | 0.05% | 482 |
|
|
2023
Q1 | $48M | Sell |
493,862
-8,262
| -2% | -$857K | 0.06% | 457 |
|
|
2022
Q4 | $52M | Sell |
502,124
-53,169
| -10% | -$4.99M | 0.06% | 442 |
|
|
2022
Q3 | $47.1M | Sell |
555,293
-43,066
| -7% | -$3.83M | 0.06% | 446 |
|
|
2022
Q2 | $49.6M | Sell |
598,359
-5,289
| -0.9% | -$421K | 0.06% | 447 |
|
|
2022
Q1 | $46.5M | Sell |
603,648
-521,126
| -46% | -$43.6M | 0.05% | 519 |
|
|
2021
Q4 | $99.4M | Buy |
1,124,774
+41,888
| +4% | +$3.46M | 0.1% | 253 |
|
|
2021
Q3 | $83.7M | Sell |
1,082,886
-132,988
| -11% | -$10.5M | 0.09% | 283 |
|
|
2021
Q2 | $101M | Buy |
1,215,874
+86,213
| +8% | +$6.83M | 0.11% | 233 |
|
|
2021
Q1 | $85.3M | Buy |
1,129,661
+299,286
| +36% | +$24.4M | 0.1% | 248 |
|
|
2020
Q4 | $72.8M | Sell |
830,375
-184,481
| -18% | -$14.6M | 0.1% | 274 |
|
|
2020
Q3 | $77.2M | Sell |
1,014,856
-129,950
| -11% | -$13.1M | 0.12% | 204 |
|
|
2020
Q2 | $141M | Buy |
1,144,806
+387,808
| +51% | +$38.5M | 0.24% | 95 |
|
|
2020
Q1 | $64M | Sell |
756,998
-109,093
| -13% | -$9.4M | 0.14% | 189 |
|
|
2019
Q4 | $73.2M | Buy |
866,091
+8,866
| +1% | +$670K | 0.13% | 211 |
|
|
2019
Q3 | $57.8M | Sell |
857,225
-391,836
| -31% | -$30.2M | 0.11% | 249 |
|
|
2019
Q2 | $107M | Sell |
1,249,061
-12,847
| -1% | -$1.1M | 0.2% | 113 |
|
|
2019
Q1 | $112M | Buy |
1,261,908
+174,499
| +16% | +$16.2M | 0.22% | 99 |
|
|
2018
Q4 | $92.6M | Sell |
1,087,409
-140,091
| -11% | -$13.3M | 0.22% | 86 |
|
|
2018
Q3 | $119M | Buy |
1,227,500
+523,649
| +74% | +$52.3M | 0.22% | 86 |
|
|
2018
Q2 | $66.3M | Buy |
703,851
+87,468
| +14% | +$7.66M | 0.14% | 146 |
|
|
2018
Q1 | $50M | Buy |
616,383
+30,545
| +5% | +$2.62M | 0.11% | 193 |
|
|
2017
Q4 | $52.2M | Buy |
585,838
+10,900
| +2% | +$948K | 0.12% | 180 |
|
|
2017
Q3 | $53.5M | Buy |
574,938
+144,651
| +34% | +$12.8M | 0.14% | 157 |
|
|
2017
Q2 | $39.1M | Buy |
430,287
+42,730
| +11% | +$3.89M | 0.1% | 224 |
|
|
2017
Q1 | $34M | Sell |
387,557
-86,505
| -18% | -$7.7M | 0.09% | 256 |
|
|
2016
Q4 | $39.3M | Buy |
474,062
+122,469
| +35% | +$10.5M | 0.12% | 190 |
|
|
2016
Q3 | $32.5M | Sell |
351,593
-47,223
| -12% | -$4.45M | 0.1% | 243 |
|
|
2016
Q2 | $31M | Sell |
398,816
-45,955
| -10% | -$3.91M | 0.1% | 247 |
|
|
2016
Q1 | $36.7M | Sell |
444,771
-727,546
| -62% | -$59.2M | 0.12% | 202 |
|
|
2015
Q4 | $123M | Sell |
1,172,317
-295,520
| -20% | -$30.9M | 0.32% | 55 |
|
|
2015
Q3 | $155M | Sell |
1,467,837
-280,208
| -16% | -$37.4M | 0.45% | 18 |
|
|
2015
Q2 | $239M | Sell |
1,748,045
-24,051
| -1% | -$2.98M | 0.62% | 9 |
|
|
2015
Q1 | $221M | Buy |
1,772,096
+595,536
| +51% | +$63.1M | 0.65% | 10 |
|
|
2014
Q4 | $106M | Buy |
1,176,560
+21,164
| +2% | +$1.76M | 0.36% | 40 |
|
|
2014
Q3 | $83.4M | Buy |
1,155,396
+208,123
| +22% | +$13.7M | 0.33% | 38 |
|
|
2014
Q2 | $58.9M | Buy |
947,273
+35,990
| +4% | +$2.17M | 0.24% | 62 |
|
|
2014
Q1 | $62.2M | Sell |
911,283
-58,014
| -6% | -$4.28M | 0.27% | 45 |
|
|
2013
Q4 | $68.2M | Buy |
969,297
+265,400
| +38% | +$18M | 0.33% | 34 |
|
|
2013
Q3 | $50.8M | Sell |
703,897
-14,308
| -2% | -$951K | 0.28% | 52 |
|
|
2013
Q2 | $40M | Buy |
+718,205
| New | +$44.8M | 0.26% | 63 |
|
Other funds holding BMRN
VCM
VPM
First Trust Advisors's BMRN Position: Q1 2026 in Review
First Trust Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 43% in Q1 2026, buying an estimated $29.5M and bringing the position to 1,672,491 shares worth $94.5M. The position accounts for 0.07% of the portfolio, ranked #362.
First Trust Advisors first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $239M in Q2 2015. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- First Trust Advisors held 1,672,491 shares of BioMarin Pharmaceuticals worth $94.5M as of Q1 2026.
- First Trust Advisors bought 505,692 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $29.5M.
- BioMarin Pharmaceuticals made up 0.07% of First Trust Advisors's portfolio in Q1 2026, its #362 holding.
- First Trust Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- First Trust Advisors's BioMarin Pharmaceuticals position peaked at $239M in Q2 2015.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.